ReviewDer Nervenarzt2004
[Use of i.v. immunoglobulins in neurology. Evidence-based consensus].
Review in Der Nervenarzt, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].Der Nervenarzt · 2011Review
- [Intravenous immunoglobulins in multiple sclerosis. An update].Der Nervenarzt · 2009Review
- [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies].Der Nervenarzt · 2009Review
- 9 Human Immunoglobulins.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2009Article
- New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.Therapeutic advances in neurological disorders · 2008Article
- [Immunoglobulins in primary antibody deficiency: should they also be used in sepsis and other indications?].Der Internist · 2007Review
- Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.Journal of neurology · 2006Review
- IVIG therapy in neurological disorders of childhood.Journal of neurology · 2006Review
- Basic principles of intravenous immunoglobulin (IVIg) treatment.Journal of neurology · 2006Review
- [High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update].Der Nervenarzt · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous immunoglobulins (IVIg) have become an alternative immunomodulatory treatment for neurological autoimmune disorders. On the basis of several well conducted placebo-controlled trials evidence is available supporting the efficacy of IVIg. However, of all neurological diseases, IVIg is currently only licensed for Guillain-Barré syndrome. Thus, the off-label use of IVIg has to be focussed although an effective treatment must be made available for the patients, in particular when there is no other treatment alternative. The consensus paper presented here critically discusses the modern studies investigating the use of IVIg in neurological diseases. On the basis of this evidence recommendations for the treatment with IVIg were developed. To achieve a broad and valid consensus, numerous German speaking experts in the field were involved. It is expected that this manuscript will help to ascertain a rational use of IVIg in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.